Skip to content
Storytelling Co – Lifestyle
Author:
Acepodia, Inc.
Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
November 5, 2026
Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
September 4, 2026